The real-world evidence being published in The American Journal of Managed Care has made the journal the most important journal for payers to read, according to Dana Goldman, PhD.
The real-world evidence being published in The American Journal of Managed Care (AJMC) has made the journal the most important journal for payers to read, according to Dana Goldman, PhD, Leonard D. Schaeffer Chair and director of the Schaeffer Center for Health Policy and Economics at the University of Southern California.
Transcript (slightly modified for readability)
What is the impact AJMC had on managed care over the last 20 years?
The American Journal of Managed Care is now the most important journal that payers are reading these days. It provides a mechanism to present real-world evidence, and so I'm very impressed when I read it to see what's going on not in the clinical trial world, but in the real world where patients really taking medication and being seen.
Why do you read AJMC and why do you submit your articles to AJMC?
I care about the real world. And in the clinical trials literature that's important for regulatory approval, but when it comes time to see how products are affecting people, AJMC is a very good source for that real-world evidence. And it reaches a payer audience, which is an important audience for that work.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More